A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Sponsor

Amgen (Industry)

Overall Status

Completed

CT.gov ID

NCT00037518

Collaborator

(none)

Enrollment

Study Details

This study will assess an investigational medication for patients with severe primary hyperparathyroidism or parathyroid cancer.

Condition or Disease	Intervention/Treatment	Phase
Hyperparathyroidism Parathyroid Neoplasms	Drug: AMG 073	Phase 4

Study Type:

Interventional

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.

Study Start Date :

Apr 1, 2001

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; * Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; * Not have had any type of cancer other than parathyroid carcinoma within the last 5 years.